ScienceDaily (Jan. 18, 2010) — Phase II study results of the agent ASA404 showed promise in patients with either squamous or non-squamous non-small cell lung cancer (NSCLC). Results of this study, which were presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, support ongoing Phase III studies of ASA404 in NSCLC.
